Portage Biotech Inc. (PRTG) NASDAQ

4.00

-0.1(-2.44%)

Updated at January 23 04:00PM

Currency In USD

Portage Biotech Inc.

Address

Craigmuir Chambers

Tortola, VG1110

Virgin Islands, British

Phone

203 221 7378

Sector

Healthcare

Industry

Biotechnology

Employees

7

First IPO Date

January 02, 2002

Key Executives

NameTitlePayYear Born
Dr. Ian B. Walters M.B.A., M.D.Chief Executive Officer & Chairman of Board717,8851968
Mr. Brian WileyChief Business Officer155,4221968
Dr. Robert A. Kramer Ph.D.Chief Scientific Officer185,891N/A
Adam MeleroController0N/A
Ms. Eun-Jae Park CPAChief Financial Officer01972

Description

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.